Mantle cell lymphoma

What changed: Mantle cell lymphoma

Cancer page →

Every dated change on the records linked to Mantle cell lymphoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Approval6Regulatory1Milestone9This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-08This recordMantle cell lymphoma
Facts on this page last checked
When this page itself was last checked or edited.

2026 · 2

2024 · 1

2024MilestoneIbrutinib
TRIANGLE and ECHO
Ibrutinib replaces transplant in fit patients; acalabrutinib + BR improves PFS first line in older patients.

2023 · 1

2023MilestonePirtobrutinib
Pirtobrutinib approved; ibrutinib US MCL indication withdrawn
A milestone in how this cancer is treated.

2020 · 3

2019 · 1

2019MilestoneZanubrutinib
Zanubrutinib approved
A milestone in how this cancer is treated.

2017 · 1

2017MilestoneAcalabrutinib
Acalabrutinib approved (ACE-LY-004)
A milestone in how this cancer is treated.

2014 · 1

2014ApprovalIbrutinib
Ibrutinib approved in EU
Relapsed mantle cell lymphoma; CLL after one prior therapy or with del(17p)/TP53 mutation

November 2013 · 1

2013-11-13RegulatoryIbrutinib
Ibrutinib: approval (US)
Mantle cell lymphoma (accelerated); first BTK inhibitor

2013 · 2

2008 · 1

2008MilestoneMantle cell lymphoma
MIPI prognostic index
A milestone in how this cancer is treated.

2007 · 1

2007ApprovalTemsirolimus
Temsirolimus approved in EU
Advanced RCC (poor risk); relapsed/refractory mantle cell lymphoma added 2009

1992 · 1

1992MilestoneMantle cell lymphoma
Cyclin D1 and t(11;14) define MCL
Mantle cell lymphoma recognised as a distinct entity (REAL classification 1994).